1. Home
  2. IMTX

IMTX

Immatics N.V.

Logo Immatics N.V.

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

as 04-12-2024 10:26am EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Immatics NV is a biotechnology company that is engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.

Founded: N/A Country:
Germany
Germany
Employees: N/A City: N/A
Market Cap: 1.1B IPO Year: N/A
Target Price: N/A AVG Volume (30 days): 504.9K
Analyst Decision: Buy Number of Analysts: 1
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.29 EPS Growth: N/A
52 Week Low/High: $5.92 - $13.16 Next Earning Date: 05-14-2024
Revenue: $59,996,667 Revenue Growth: -68.76%
Revenue Growth (this year): 11.75% Revenue Growth (next year): -2.14%

Share on Social Networks: